Where Wharton's jelly sits in the umbilical cord
Wharton's jelly is the gelatinous connective tissue that fills the umbilical cord, surrounding and cushioning the umbilical vessels between the placenta and the fetus. It is not a cell population in the way blood or bone marrow are; it is a structural matrix, a gel-like extracellular environment that the vessels sit inside. Wharton's jelly is rich in hyaluronic acid, collagens and growth factors.
When tissue processors recover material for allograft products, it is this matrix, along with whatever cellular and soluble content it carries, that becomes the starting material. Understanding what the matrix is made of is the starting point for understanding what a Wharton's jelly product actually is.
The major structural molecules in the matrix
Wharton's jelly is rich in hyaluronic acid, collagens and growth factors. These are structural and matrix components of the native tissue, not a description of any product's clinical effect.
None of this composition describes a drug effect. It describes what the tissue is made of before any processing happens. What survives processing, and in what concentration, is a separate empirical question answered by lot-specific testing, not by the general biology of the native tissue.
From donor tissue to a processed allograft
Trained, licensed personnel recover tissue at scheduled full-term C-section deliveries from a screened, consenting donor. Tissue is processed within 48 hours of recovery. Processing is described by suppliers as following FDA regulation and AATB/AABB guidance, a description of the process, not a certification that should be taken as a blanket safety or efficacy claim.
Depending on the format, the final product may be cryopreserved using slow-rate freezing and stored at -80 degrees Celsius for shipment on dry ice, or lyophilized (freeze-dried) into a shelf-stable format that does not require cold-chain storage. Cryopreserved and lyophilized formats have different documented handling requirements. Confirm the insert for the specific product.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
What the published evidence does and does not establish
Published research on Wharton's jelly-derived material for regenerative use is still early-stage, consisting mostly of small studies rather than large controlled trials. Reviews of this literature describe the tissue's native composition (hyaluronic acid, collagens and growth factors) fairly consistently. They note that how that composition translates into any defined clinical use remains an open scientific and regulatory question rather than a settled one.
This is a distinct question from live-cell content, which is addressed separately by cell-count and colony-forming studies of commercial products. A buyer evaluating a Wharton's jelly product should treat matrix composition and cell content as two different things that each need their own documentation.
Reading a certificate of analysis for a Wharton's jelly product
A lot-specific certificate of analysis is the practical way to connect the general biology above to a specific vial. It should identify the donor eligibility screening performed, the sterility and release testing completed for that lot, and the storage and handling parameters validated for the format shipped. Composition figures published generically for Wharton's jelly as a tissue type are not a substitute for lot-specific release data.
- Donor eligibility and screening documentation
- Lot-specific sterility and release testing results
- Storage, handling and stability parameters for the format received
- Any characterization data the supplier makes available for that lot
Frequently asked questions
Is Wharton's jelly a type of cell, or a tissue?+
It is a tissue — specifically the gelatinous extracellular matrix that fills the umbilical cord and surrounds the umbilical vessels, not a defined cell population.
What are the main structural components of Wharton's jelly?+
Hyaluronic acid, collagens and growth factors make up the composition of the extracellular matrix described in the published literature.
Does the processing method (cryopreserved vs lyophilized) change what's in the product?+
Yes. Cryopreservation and lyophilization are different preservation approaches with different handling requirements, and neither should be assumed to preserve matrix composition or cell content identically to the native tissue.
Does matrix composition tell me whether a product contains viable cells?+
No. Matrix composition (hyaluronic acid, collagens and growth factors) and live-cell content are separate questions that require separate documentation, such as viability assays, to answer.